Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Meningitis b vaccine booster shows promise in kids

NCT ID NCT01621945

Vaccine Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a fourth dose of the MenBVac vaccine boosts protection against meningitis B in children. Researchers measured immune responses in 120 children before and after the booster. The goal was to see if the vaccine maintains protective antibody levels over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MenBVac vaccine
What this could lead to
If successful, this could confirm that a fourth dose of MenBVac provides lasting protection against meningitis B in children.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all children or other meningitis strains. The vaccine may not provide long-term immunity for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

120 people

The number who actually took part.

Start date

Apr 2012

Finished

Sep 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 8 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * children born between 06/04/2004 and 17/04/2008, living in Neufchatel en Bray,and Having participated to the first study, * children who Have to be Vaccinated MenBVac® for the four times, * parental authority(ies)assent. Exclusion Criteria: * no parental authority(ies)assent, * no blood sample, * impossibility of fourth vaccination, * children yet vaccinated or non eligible for vaccination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neisseria meningitidis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neisseria meningitidis

Contacts and locations

Locations

  • Maison Du Département

    Neufchâtel-en-Bray, 76270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.